Showing results (1-10 of 128) with videos related to
Sort By:
Pageof 13
CNS Oncology|November 4, 2014
Introduction of our new associate editorAnnick Desjardins, Roshaine GunawardanaNeuro-Oncology Practice|January 31, 2022
Convection-enhanced delivery for high-grade gliomaJennifer H Kang, Annick DesjardinsNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|June 8, 2022
Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical PracticeMadison L Shoaf, Annick DesjardinsClinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2015
CCR 20th Anniversary Commentary: Bevacizumab in the Treatment of Glioblastoma--The Progress and the LimitationsNataliya Mar, Annick Desjardins, James J VredenburghOncology (Williston Park, N.Y.)|March 18, 2016
Vaccine Therapy, Oncolytic Viruses, and GliomasAnnick Desjardins, Gordana Vlahovic, Henry S FriedmanNeuro-Oncology|February 12, 2013
Imaging descriptors improve the predictive power of survival models for glioblastoma patientsMaciej Andrzej Mazurowski, Annick Desjardins, Jordan Milton MalofBiologics : Targets & Therapy|August 27, 2009
Current available therapies and future directions in the treatment of malignant gliomasAnnick Desjardins, David A Reardon, James J VredenburghAJNR. American Journal of Neuroradiology|May 14, 2004
Technical modification in the intracarotid chemotherapy and osmotic blood-brain barrier disruption procedure to prevent the relapse of carboplatin-induced orbital pseudotumorDavid Fortin, Joseph A Salamé, Annick Desjardins, et al.Cancer|May 10, 2005
Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experienceDavid Fortin, Annick Desjardins, Andrew Benko, et al.Neuro-Oncology|September 12, 2008
Experience with irinotecan for the treatment of malignant gliomaJames J Vredenburgh, Annick Desjardins, David A Reardon, et al.Pageof 13